Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Active Inflammatory Bowel Disease
Loss of total mass of muscles (catabolism) is a serious clinical problem in patients with active inflammatory bowel disease (IBD). The investigators have earlier shown that the liver plays an important role in this stress-catabolism by increasing the production of urea during the inflammatory process.
The purpose of this study is to examine the effect of the anti-inflammatory drugs prednisolone and infliximab on the regulation of the urea synthesis in patients with active ulcerative colitis and Crohn's disease.
Inflammatory Bowel Diseases
|Study Design:||Observational Model: Case-Crossover
Time Perspective: Prospective
|Official Title:||Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Patients With Active Ulcerative Colitis and Crohn's Disease|
- Functional Hepatic Nitrogen Clearance [ Time Frame: Before and one week after treatment ] [ Designated as safety issue: No ]
- Clinical and biochemical measures of inflammation [ Time Frame: Before and one week after treatment ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Serum, plasma and urine.
|Study Start Date:||January 2009|
|Study Completion Date:||December 2011|
Active inflammatory bowel disease
Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00955123
|Department of Medicine V, Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Karen Louise Thomsen, MD||Aarhus University Hospital|